Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 547 citing articles:

Treatment of Multiple Sclerosis: A Review
Stephen L. Hauser, Bruce Cree
The American Journal of Medicine (2020) Vol. 133, Iss. 12, pp. 1380-1390.e2
Open Access | Times Cited: 643
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Dennis S. W. Lee, Olga L. Rojas, Jennifer L. Gommerman
Nature Reviews Drug Discovery (2020) Vol. 20, Iss. 3, pp. 179-199
Open Access | Times Cited: 462
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Simon Faissner, Jason R. Plemel, Ralf Gold, et al.
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 12, pp. 905-922
Closed Access | Times Cited: 373
Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology
Luiz G. Almeida, Hayley Thode, Yekta Eslambolchi, et al.
Pharmacological Reviews (2022) Vol. 74, Iss. 3, pp. 714-770
Open Access | Times Cited: 276
Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines
Masaru Tanaka, József Toldi, László Vécsei
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 7, pp. 2431-2431
Open Access | Times Cited: 212
Smouldering multiple sclerosis: the ‘real MS’
Gavin Giovannoni, Veronica Popescu, Jens Wuerfel, et al.
Therapeutic Advances in Neurological Disorders (2022) Vol. 15
Open Access | Times Cited: 177
Secondary Progressive Multiple Sclerosis
Bruce Cree, Douglas L. Arnold, Jeremy Chataway, et al.
Neurology (2021) Vol. 97, Iss. 8, pp. 378-388
Open Access | Times Cited: 170
Rituximab for the treatment of multiple sclerosis: a review
Clara Grazia Chisari, Eleonora Sgarlata, Sebastiano Arena, et al.
Journal of Neurology (2021) Vol. 269, Iss. 1, pp. 159-183
Open Access | Times Cited: 153
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis
Heather Yong, V. Wee Yong
Nature Reviews Neurology (2021) Vol. 18, Iss. 1, pp. 40-55
Closed Access | Times Cited: 117
Bruton tyrosine kinase inhibitors for multiple sclerosis
Julia Krämer, Amit Bar‐Or, Timothy J. Turner, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 5, pp. 289-304
Open Access | Times Cited: 99
Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges
Jinming Han, Violeta Chiţu, E. Richard Stanley, et al.
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 4
Open Access | Times Cited: 98
Epidemiology and Pathophysiology of Multiple Sclerosis
Melanie Ward, Myla Goldman
CONTINUUM Lifelong Learning in Neurology (2022) Vol. 28, Iss. 4, pp. 988-1005
Closed Access | Times Cited: 97
Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics
Emily Kamma, Wendy O Lasisi, Cole D. Libner, et al.
Journal of Neuroinflammation (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 94
Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target
Rongzeng Liu, Shushu Du, Lili Zhao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 79
Changes in Gut Microbiota and Multiple Sclerosis: A Systematic Review
Alba Ordoñez-Rodriguez, Pablo Román, Lola Rueda‐Ruzafa, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 5, pp. 4624-4624
Open Access | Times Cited: 58
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis
Anne H. Cross, Jeffrey M. Gelfand, Simon Thebault, et al.
JAMA Neurology (2024) Vol. 81, Iss. 4, pp. 373-373
Open Access | Times Cited: 35
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
Patrick Vermersch, Cristina Granziera, Yang Mao‐Draayer, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 7, pp. 589-600
Closed Access | Times Cited: 34
Cellular architecture of evolving neuroinflammatory lesions and multiple sclerosis pathology
Petra Kukanja, Christoffer Mattsson Langseth, Leslie A. Kirby, et al.
Cell (2024) Vol. 187, Iss. 8, pp. 1990-2009.e19
Open Access | Times Cited: 34
Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis
Massimiliano Calabrese, Paolo Preziosa, Antonio Scalfari, et al.
Annals of Neurology (2024) Vol. 96, Iss. 1, pp. 1-20
Open Access | Times Cited: 28
Multiple sclerosis: emerging epidemiological trends and redefining the clinical course
Emilio Portaccio, Melinda Magyari, Eva Havrdová, et al.
The Lancet Regional Health - Europe (2024) Vol. 44, pp. 100977-100977
Open Access | Times Cited: 24
Prediction of clinical progression in nervous system diseases: plasma glial fibrillary acidic protein (GFAP)
Xiaoxiao Zheng, Jingyao Yang, Yiwei Hou, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 17
Immunological Aspects of Approved MS Therapeutics
Paulus Rommer, Ron Milo, May Han, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 137
Mechanisms underlying progression in multiple sclerosis
Martina Absinta, Hans Lassmann, Bruce D. Trapp
Current Opinion in Neurology (2020) Vol. 33, Iss. 3, pp. 277-285
Open Access | Times Cited: 128
Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development
Valentina Pegoretti, Kathryn A. Swanson, John R. Bethea, et al.
Oxidative Medicine and Cellular Longevity (2020) Vol. 2020, pp. 1-19
Open Access | Times Cited: 119
Emerging links between cerebrovascular and neurodegenerative diseases—a special role for pericytes
Urban Lendahl, Per Nilsson, Christer Betsholtz
EMBO Reports (2019) Vol. 20, Iss. 11
Open Access | Times Cited: 117
Page 1 - Next Page

Scroll to top